P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
Journal Article
2009
Permanent link to this Item
Authors
Journal Title
Retrovirology
Link to Journal
Journal ISSN
Volume Title
Publisher
BioMed Central Ltd
Publisher
University of Cape Town
Department
Faculty
Series
Abstract
Mycobacterium bovis BCG (BCG) has a number of characteristics that give it great potential to act as a vehicle for the delivery of recombinant vaccines. However, its success depends on overcoming the challenges of poor antigen expression levels and genetic instability. Our studies using an optimized mycobacterial shuttle vector which utilizes the Mycobacterium tuberculosis mtrA promoter, induced upon infection of macrophages, and the M. tuberculosis 19 kDa signal sequence may overcome these issues. We have used this system to generate a recombinant BCG (rBCG) expressing HIV-1 subtype C full length Gag or reverse transcriptase (RT).
Description
Reference:
Stutz, H., Powles, R., Shephard, E. G., & Williamson, A. (2009). P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice. Retrovirology, 6(Suppl 3), P417.